34 studies found for:    " September 30, 2013":" October 30, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 30, 2013":" October 30, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Conditions: HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: TAF;   Drug: Placebo to match TAF;   Drug: E/C/F/TAF;   Drug: Pre-existing ARV regimen;   Drug: ATV
2 Completed Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children
Condition: HIV Infection
Interventions: Drug: ABC Twice Daily;   Drug: ABC Once Daily;   Drug: 3TC Once Daily;   Drug: 3TC Twice Daily
3 Recruiting Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Conditions: Acquired Immune Deficiency Syndrome Virus;   Acquired Immunodeficiency Syndrome Virus;   AIDS Virus;   Human Immunodeficiency Virus;   Human Immunodeficiency Viruses
4 Recruiting Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Conditions: HIV;   HIV-associated Neurocognitive Disorder;   Neurotoxicity
Intervention: Drug: switch efavirenz (EFV) to raltegravir (RAL)
5 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CD34 Stem Cell Selection Therapy
6 Recruiting Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
Condition: HIV-1 Infection
Interventions: Drug: Raltegravir;   Drug: Efavirenz
7 Active, not recruiting Expansion to Interdisciplinary HIV Prevention in Women
Conditions: HIV;   AIDS;   Fetal Alcohol Syndrome;   Alcohol Related Neurodevelopmental Disorder
Interventions: Behavioral: Opt-in or Opt-out testing;   Behavioral: Focus Group
8 Active, not recruiting Feasibility of an Exercise Intervention
Condition: HIV
Intervention: Other: HOME-EX
9 Recruiting Barbershop Talk: HIV Prevention for African American Heterosexual Men
Condition: HIV
Interventions: Behavioral: BTWB intervention;   Behavioral: Cancer prevention and screening
10 Recruiting HIV-related Accelerated Aging of the Airway Epithelium
Conditions: HIV;   COPD;   Chronic Obstructive Pulmonary Disease;   Smoking
Intervention: Genetic: Examination of the interaction of HIV directly on the small airway epithelium
11 Recruiting Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Condition: HIV
Intervention: Drug: alendronate/vitamin D
12 Recruiting Smoking Cessation for People Living With HIV/AIDS
Conditions: HIV;   AIDS;   Nicotine Dependence
Interventions: Drug: Bupropion;   Behavioral: Brief Counseling;   Behavioral: High-magnitude prize contingency management;   Behavioral: Monitored support to quit smoking;   Behavioral: No additional treatment;   Behavioral: Prize contingency management for abstinence;   Behavioral: Low intensity prize contingency management
13 Active, not recruiting N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
Conditions: HIV;   Endothelial Dysfunction;   Oxidative Stress
Interventions: Dietary Supplement: PharmaNAC (N-acetylcysteine);   Dietary Supplement: Matching placebo
14 Recruiting Comparing Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania
Condition: HIV
Interventions: Other: NAC (Nutritional Assessment and Counseling);   Other: Cash Transfer;   Other: Food Assistance
15 Not yet recruiting Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth
Condition: HIV
Intervention: Behavioral: Motivational Enhancement Therapy (MET)
16 Completed Mother Infant Retention for Health: MIR4Health
Condition: HIV/AIDS
Intervention: Behavioral: Study Intervention for Retention (APFU)
17 Completed
Has Results
PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months
Condition: HIV Infection
Interventions: Other: Intervention 1: PK assessment while on Twice Daily Abacavir;   Other: Intervention 2: PK assessment while on Once Daily Abacavir
18 Recruiting The Safety and Immunogenicity of a Potential HIV Vaccine
Condition: HIV Infections
Intervention: Biological: CN54gp140 mixed with GLA-AF
19 Completed Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: CBZ
20 Active, not recruiting Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density
Condition: HIV-1 Infection
Interventions: Drug: Dolutegravir, 50mg every 24 hours;   Drug: Protease Inhibitor/ritonavir

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Indicates status has not been verified in more than two years